Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference
The H.C. Wainwright 26th Annual Global Investment Conference is being held on-line and in person, Sept. 9-11. Clene management will give a virtual presentation of the company’s most recent achievements and results and will hold one-on-one investor meetings. Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering new hope for patients with neurodegenerative conditions. The company is seeking FDA approval to file a new drug application for CNM-Au8, using the accelerated approval pathway for treatment of ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to…